# FDA Approves First Treatment for Neurologic Symptoms of Type 3 Gaucher Disease

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/neurology/generalneurology/123960) · 2026-11-19 · Medicine
Page: https://themorning.science/story/fda-approves-first-treatment-for-neurologic-symptoms-of-type-3-gaucher-disease-f1cfe04ec82125f5
Kind: launch · Impact: medium

## In brief

- The FDA approved venglustat (brand name Infilbray) tablets.
- It is the first treatment for neurologic symptoms of type 3 Gaucher disease.
- It is approved for adults and children weighing at least 15 kg.

## Why it matters

It gives clinicians the first approved option for the neurologic symptoms of type 3 Gaucher disease, a rare inherited condition that previously lacked a treatment targeting those symptoms.

## Timeline

- 2026-11-19: FDA approval of venglustat for neurologic symptoms of type 3 Gaucher disease, as reported by MedPage Today

## Coverage

- [FDA Approves First Treatment for Neurologic Symptoms of Type 3 Gaucher Disease](https://www.medpagetoday.com/neurology/generalneurology/123960) — MedPageToday.com - medical news for physicians, 2026-11-19

Tags: gaucher disease, fda approval, rare disease, neurology, venglustat

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
